-
Medical Costs in Patients with Pulmonary Arterial Hypertension (PAH) on Oral Triple Therapy including Selexipag in the United States (US): A retrospective Claims-Based Study
Mar 10, 2025, 14:00 PM -
Automating Health Economic Model Quality Check With a Model Generator
Mar 10, 2025, 14:00 PM -
Characteristics of Adults With Type 2 Diabetes Who Are Not Treated With A Glucose-Lowering Agent: A Retrospective Cohort Study
Mar 10, 2025, 14:00 PM -
Inclusion of Health-Related Quality of Life (HRQoL) and Other Patient-Reported Outcomes (PROs) in the United States Food and Drug Administration (FDA) Labels
Mar 10, 2025, 14:00 PM -
Prospective, Comparative Study Between Fully-Automated and Semi-Automated Whole Blood Processing Systems in a Colombian Blood Bank Center
Mar 10, 2025, 14:00 PM -
Assessability of Single-Arm Studies (SAT) Under Joint Clinical Assessment (JCA): Whether Drugs Assessed With SAT in the Last Years Would Fit Under the New EU HTA Framework?
Mar 10, 2025, 14:00 PM -
A Structured Literature Review on Survival, Complications, Disease Transformation, Treatment Pattern and Unmet Need Among Patients With Essential Thrombocythemia
Mar 10, 2025, 14:00 PM -
Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Degludec for the Treatment of Patients With Type 2 Diabetes Mellitus in China
Mar 10, 2025, 14:00 PM -
Predicting Future Type 1 Diabetes Onset Risk; A Machine Learning Approach
Mar 10, 2025, 14:00 PM -
Real-World Adjuvant Nivolumab Utilization in Surgically Treated Muscle-Invasive Bladder Cancer Patients within U.S. Community Oncology Practice
Mar 10, 2025, 14:00 PM -
Association Between Vaginal Progesterone Use and Risk of Preterm Birth Among High-Risk Pregnancies: A Real-World Evidence Study
Mar 10, 2025, 14:00 PM -
Benchmarking Disease Prevalence in a Large Scale Electronic Health Record Data Network: An Assessment of Chronic and Rare Disease in the United States in 2023
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Pembrolizumab for Previously treated MSI-H/dMMR Solid Tumors in Canada
Mar 10, 2025, 14:00 PM -
Real-World Healthcare Resource Utilization (HCRU) and Economic Burden Among Patients With High-Risk Carcinoma-In-Situ (CIS) Non-Muscle Invasive Bladder Cancer (NMIBC) Using a Large Medicare Dataset
Mar 10, 2025, 14:00 PM -
Assessing the Economic Impact of Biosimilars in the U.S.: A cost analysis of Infliximab, Trastuzumab, and Rituximab
Mar 10, 2025, 14:00 PM -
Developing a Value Assessment Framework for Modified New Drugs In China
Mar 10, 2025, 14:00 PM -
Trends in FDA Approvals of Cardiovascular Drugs from 1980 to 2024
Mar 10, 2025, 14:00 PM -
Costs of Alzheimer's Disease and Related Dementia among Medicare Beneficiaries in the United States
Mar 10, 2025, 14:00 PM -
Baseline Risk of Hospitalization and Mortality in High-Risk Subgroups of a Nirmatrelvir/Ritonavir Treatment-Eligible Population With Mild-to-Moderate COVID-19 in the United States: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Acute Care visits and Readmissions Among Commercial Plan Enrollees with Heart Failure with Preserved Ejection Fraction (HFpEF) by Obesity Classes
Mar 10, 2025, 14:00 PM
